TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. [PDF]
Sci RepMitsukawa K +9 more
europepmc +1 more source
Correction to "The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report". [PDF]
Clin Case Repeuropepmc +1 more source
A Simple, Sensitive, and Greener HPLC-DAD Method for the Simultaneous Analysis of Two Novel Orexin Receptor Antagonists. [PDF]
ACS OmegaIqbal M +4 more
europepmc +1 more source
Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database. [PDF]
Front PharmacolJiang M, Li H, Kong L.
europepmc +1 more source
A letter to the editor regarding "Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis." by Na et al. [PDF]
SleepMoline M, Yardley J, Cheng JY.
europepmc +1 more source
Maternal exposure to Di-n-butyl phthalate (DBP) inhibit orexin receptor 1 (OX1R) expression to prevent Sertoli cells proliferation through the AKT signaling pathway. [PDF]
Toxicol Res (Camb)Xie Z +7 more
europepmc +1 more source
Orexin receptor 2 agonist activates diaphragm and genioglossus muscle through stimulating inspiratory neurons in the pre-Bötzinger complex, and phrenic and hypoglossal motoneurons in rodents. [PDF]
PLoS OneYamada R +3 more
europepmc +1 more source
Related searches:
Orexin Receptor Antagonists and Insomnia
Current Psychiatry Reports, 2022We review recent evidence on the use of orexin receptor antagonists (ORAs) for treating insomnia. We evaluate studies on five dual ORAs and one selective ORA.Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia.
Xin, Wu +4 more
openaire +2 more sources